Fulgent Genetics

Company History and Evolution

Fulgent Genetics began as a specialized genetic testing laboratory focused on inherited diseases and oncology. Its early growth was fueled by the development of a proprietary technology platform that allowed clinicians and researchers to order customizable gene panels rather than being limited to fixed, predetermined test menus.

During the COVID-19 pandemic, Fulgent rapidly scaled its operations to become one of the largest providers of SARS-CoV-2 testing in the United States. This dramatic expansion in capacity and revenue allowed the company to invest heavily in new laboratories, technology infrastructure, and strategic acquisitions. The company leveraged the resources generated during this period to diversify its business and reduce its dependence on any single testing category.

In recent years, Fulgent has expanded into therapeutic development through its subsidiary focused on oncology drug discovery, marking a significant strategic move from a pure diagnostics company toward an integrated diagnostics and therapeutics organization.

Core Business Segments

Fulgent operates across two primary business areas: laboratory services and therapeutic development.

Laboratory Services

The laboratory services segment encompasses the company's diagnostic testing operations. This includes genetic testing, anatomic and clinical pathology, oncology diagnostics, reproductive health screening, and infectious disease testing. Fulgent's laboratories are equipped to handle high-volume sample processing using next-generation sequencing and other advanced molecular technologies.

Therapeutic Development

Through its therapeutics subsidiary, Fulgent is developing a pipeline of drug candidates, with an emphasis on oncology. This division utilizes proprietary nanoencapsulation and drug delivery technologies aimed at improving the efficacy and reducing the toxicity of cancer treatments. This represents the company's effort to move beyond diagnostics into the broader healthcare value chain.

Products and Services

Genetic Testing

Fulgent offers an extensive catalog of genetic tests covering thousands of genes and a wide spectrum of conditions. Key offerings include:

• Hereditary cancer testing that screens for genetic mutations associated with increased risk of cancers such as breast, ovarian, colorectal, and other inherited cancer syndromes.

• Comprehensive and customizable gene panels that allow clinicians to select specific genes relevant to a patient's clinical presentation, providing flexibility not commonly available with fixed-panel competitors.

• Whole exome sequencing and whole genome sequencing services for the diagnosis of rare and complex genetic disorders.

• Carrier screening designed to identify individuals who carry genetic variants that could be passed to their children, supporting reproductive planning.

• Pediatric and developmental disorder testing aimed at diagnosing genetic conditions affecting children, including neurodevelopmental and metabolic disorders.

• Cardiology genetic testing for inherited heart conditions such as cardiomyopathies and arrhythmias.

Oncology and Pathology Services

Fulgent provides a suite of oncology-focused diagnostic services through its laboratory operations and acquired pathology businesses. These include:

• Solid tumor profiling and molecular testing that helps oncologists understand the genetic characteristics of a patient's tumor to guide targeted therapy decisions.

• Hematopathology and anatomic pathology services that combine traditional pathology with molecular diagnostics for comprehensive cancer diagnosis.

• Liquid biopsy and circulating tumor DNA analysis used to detect and monitor cancer through blood-based testing.

Reproductive Health

The company offers reproductive and women's health testing, including prenatal and preconception screening services. These tests support family planning by identifying genetic risks and providing actionable information to expectant parents and clinicians.

Infectious Disease Testing

Building on its experience during the COVID-19 pandemic, Fulgent maintains capabilities in infectious disease diagnostics. This includes respiratory pathogen panels, sexually transmitted infection testing, and other molecular infectious disease assays. The company developed substantial high-throughput testing infrastructure that continues to support its broader diagnostic offerings.

Research and Pharmaceutical Services

Fulgent provides services to pharmaceutical companies, research institutions, and biotechnology firms. These include companion diagnostic development, clinical trial support, biomarker analysis, and custom sequencing projects. The company's technology platform and laboratory capacity make it a partner for organizations requiring large-scale genomic data generation and analysis.

Technology Platform

A defining feature of Fulgent is its proprietary technology platform, which integrates wet laboratory processes, bioinformatics, and data analysis. The platform was engineered to be flexible and scalable, enabling the company to offer a large number of genes and test combinations efficiently and cost-effectively.

The bioinformatics infrastructure underpinning Fulgent's services allows for the interpretation of complex genomic data, transforming raw sequencing output into clinically meaningful reports. This combination of laboratory automation and computational analysis is central to the company's ability to deliver accurate results at scale and at competitive pricing.

Acquisitions and Strategic Growth

Fulgent has pursued an active acquisition strategy to broaden its capabilities and geographic reach. The company has acquired pathology laboratories and diagnostic businesses that complement its existing genetics expertise, expanding its presence in anatomic pathology and oncology diagnostics. These acquisitions have helped Fulgent build a more comprehensive testing menu and establish relationships with hospitals, physician practices, and health systems.

Markets Served

Fulgent serves a diverse customer base that includes:

• Hospitals and health systems requiring diagnostic testing services.
• Physician practices and individual clinicians ordering genetic and pathology tests.
• Reference laboratories seeking specialized testing capabilities.
• Academic and research institutions conducting genomic studies.
• Pharmaceutical and biotechnology companies needing diagnostic and trial support services.
• Government and public health agencies requiring large-scale testing solutions.

Corporate Profile

Headquartered in El Monte, California, Fulgent Genetics operates laboratories and facilities that support its national testing operations. The company emphasizes innovation, technological integration, and the combination of diagnostics with emerging therapeutic development. Led by founder and chief executive Ming Hsieh, Fulgent continues to pursue a strategy of diversification, aiming to balance its established diagnostics business with longer-term investments in oncology therapeutics.

Conclusion

Fulgent Genetics has evolved from a focused genetic testing laboratory into a diversified molecular diagnostics and life sciences company. By combining a proprietary, flexible technology platform with an expanding menu of genetic, oncology, pathology, reproductive, and infectious disease tests, the company has established itself as a significant player in the clinical diagnostics market. Its move into therapeutic development further reflects an ambition to participate across the broader healthcare continuum, leveraging its technological and financial foundation to pursue growth in both diagnostics and treatment.